» Articles » PMID: 16291981

Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2005 Nov 18
PMID 16291981
Citations 230
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but are typically prescribed with minimal or no lifestyle modification. This practice is likely to limit therapeutic benefits.

Methods: In this one-year trial, we randomly assigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care provider in eight visits of 10 to 15 minutes each; lifestyle-modification counseling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling delivered by a primary care provider in eight visits of 10 to 15 minutes each. All subjects were prescribed a diet of 1200 to 1500 kcal per day and the same exercise regimen.

Results: At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by lifestyle modification alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.001). Those in the combined-therapy group who frequently recorded their food intake lost more weight than those who did so infrequently (18.1+/-9.8 kg vs. 7.7+/-7.5 kg, P=0.04).

Conclusions: The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.

Citing Articles

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.

Sidrak W, Kalra S, Kalhan A Indian J Endocrinol Metab. 2024; 28(5):445-460.

PMID: 39676791 PMC: 11642516. DOI: 10.4103/ijem.ijem_442_23.


A partial loss-of-function variant (Ile191Val) of the TAS1R2 glucose receptor is associated with enhanced responses to exercise training in older adults with obesity: A translational study.

Serrano J, Kondo S, Link G, Brown I, Pratley R, Baskin K Metabolism. 2024; 162:156045.

PMID: 39393515 PMC: 11637915. DOI: 10.1016/j.metabol.2024.156045.


The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Abdalla M, Shah N, Deshmukh H, Sahebkar A, Ostlundh L, Al-Rifai R Adv Ther. 2024; 41(6):2168-2195.

PMID: 38683294 DOI: 10.1007/s12325-024-02848-3.


The past, present, and future of behavioral obesity treatment.

Chao A, Moore M, Wadden T Int J Obes (Lond). 2024; 49(2):196-205.

PMID: 38678143 PMC: 11729970. DOI: 10.1038/s41366-024-01525-3.


Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.

Jamal M, Alhashemi M, Dsouza C, Al-Hassani S, Qasem W, Almazeedi S Obes Surg. 2024; 34(4):1324-1332.

PMID: 38430320 DOI: 10.1007/s11695-024-07137-0.